The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies

[1]  K. Śliżewska,et al.  The role of probiotics, prebiotics and synbiotics in animal nutrition , 2018, Gut Pathogens.

[2]  L. Zitvogel,et al.  Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  F. Marincola,et al.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.

[4]  A. Andriulli,et al.  Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies , 2018, Microbiome.

[5]  L. Zitvogel,et al.  The impact of the intestinal microbiota in therapeutic responses against cancer. , 2018, Comptes rendus biologies.

[6]  J. Wargo,et al.  The gut microbiota influences anticancer immunosurveillance and general health , 2018, Nature Reviews Clinical Oncology.

[7]  A. Daud,et al.  The gut microbiota and immune checkpoint inhibitors , 2018, Human vaccines & immunotherapeutics.

[8]  B. Helmink,et al.  The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. , 2018, Cancer cell.

[9]  Kongming Wu,et al.  Gut microbiome modulates efficacy of immune checkpoint inhibitors , 2018, Journal of Hematology & Oncology.

[10]  Laurence Zitvogel,et al.  The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies , 2018, Science.

[11]  A. Cesano,et al.  Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic , 2018, Biomedicines.

[12]  K. Chamoto,et al.  Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy , 2018, Journal of internal medicine.

[13]  E. Le Chatelier,et al.  Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.

[14]  Laurence Zitvogel,et al.  Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.

[15]  Riyue Bao,et al.  The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients , 2018, Science.

[16]  E. Frenkel,et al.  Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients , 2017, Neoplasia.

[17]  A. Eggermont,et al.  Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  R. Boidot,et al.  Antibiotic Use Does Not Appear to Influence Response to Nivolumab. , 2017, Anticancer research.

[19]  K. Schalper,et al.  Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis. , 2017, JCO precision oncology.

[20]  T. Gajewski,et al.  The Microbiota: A New Variable Impacting Cancer Treatment Outcomes , 2017, Clinical Cancer Research.

[21]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[22]  A. Balar,et al.  PD-1 and PD-L1 antibodies in cancer: current status and future directions , 2017, Cancer Immunology, Immunotherapy.

[23]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[24]  T. Schumacher,et al.  Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A Review. , 2016, JAMA oncology.

[25]  P. Ascierto,et al.  Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment , 2016, Oncotarget.

[26]  J. Eisen,et al.  Host Gut Motility Promotes Competitive Exclusion within a Model Intestinal Microbiota , 2016, PLoS biology.

[27]  Fan Yang,et al.  Specific immunotherapy plus Clostridium butyricum alleviates ulcerative colitis in patients with food allergy , 2016, Scientific Reports.

[28]  Peer Bork,et al.  Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees , 2016, Nucleic Acids Res..

[29]  L. Zitvogel,et al.  Microbiome and Anticancer Immunosurveillance , 2016, Cell.

[30]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[31]  C. Huttenhower,et al.  Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis , 2016, Nature Communications.

[32]  S. Dowd,et al.  Pglyrp-Regulated Gut Microflora Prevotella falsenii, Parabacteroides distasonis and Bacteroides eggerthii Enhance and Alistipes finegoldii Attenuates Colitis in Mice , 2016, PloS one.

[33]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[34]  Jason B. Williams,et al.  Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.

[35]  B. Bohannan,et al.  Individual Members of the Microbiota Disproportionately Modulate Host Innate Immune Responses. , 2015, Cell host & microbe.

[36]  Qifeng Gui,et al.  Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model. , 2015, Genetics and molecular research : GMR.

[37]  Jeroen Raes,et al.  How informative is the mouse for human gut microbiota research? , 2015, Disease Models & Mechanisms.

[38]  P. Moayyedi,et al.  Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis , 2014, The American Journal of Gastroenterology.

[39]  F. Marincola,et al.  Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment , 2013, Science.

[40]  M. Horinaka,et al.  Clostridium butyricum MIYAIRI 588 shows antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-8. , 2013, International journal of oncology.

[41]  T. Matsui,et al.  Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease , 2012, Journal of Gastroenterology.

[42]  S. Miehlke,et al.  Prevalence of Bacteroides and Prevotella spp. in ulcerative colitis. , 2006, Journal of medical microbiology.

[43]  F. Bäckhed,et al.  Obesity alters gut microbial ecology. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  C. Neut,et al.  Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease , 2002, American Journal of Gastroenterology.